We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Prophylactic Photodynamic Therapy to Organ Transplant Patients

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2008 by Bispebjerg Hospital.
Recruitment status was:  Not yet recruiting
ClinicalTrials.gov Identifier:
First Posted: August 17, 2006
Last Update Posted: June 2, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bispebjerg Hospital
To evaluate a possible prophylactic efficacy of photodynamic therapy on the incidence of non-melanoma skin cancer, actinic keratoses, warts and keratoses in recently organ transplanted recipients.

Condition Intervention
Organ Transplants Procedure: Photodynamic Therapy

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single

Further study details as provided by Bispebjerg Hospital:

Estimated Enrollment: 50
Study Start Date: April 2009

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Organ transplant recipients.
  • Age 40 years or older.

Exclusion Criteria:

  • Patients younger than 40 years and older than 70 years.
  • Clinical signs of skin cancer, actinic keratoses or warts at the time of inclusion.
  • Previous photodynamic therapy to the skin areas investigated.
  • Pregnancy or breast feeding patients.
  • Patients with porphyria.
  • Patients with a tendency to produce hypertrophic scars or keloids.
  • Patients with known allergy to Metvix.
  • Patients who are not considered able to follow the treatment protocol (e.g. severely alcoholic patients, dementia patients, mentally ill patients etc.).
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00365521

Contact: Merete Hædersdal, MD, PhD, DrMedSci +45 35316002 mhaedersdal@dadlnet.dk

Bispebjerg Hospital Not yet recruiting
Copenhagen, Copenhagen NV, Denmark, 2400
Contact: Merete Hædersdal    +45 35 31 60 02    mhaedersdal@dadlnet.dk   
Sponsors and Collaborators
Bispebjerg Hospital
Principal Investigator: Merete Hædersdal, MD, PhD, DrMedSci Bispebjerg Hospital
  More Information

ClinicalTrials.gov Identifier: NCT00365521     History of Changes
Other Study ID Numbers: KF-01-314759
First Submitted: August 15, 2006
First Posted: August 17, 2006
Last Update Posted: June 2, 2008
Last Verified: May 2008

Keywords provided by Bispebjerg Hospital:
Organ transplant patients receiving immunosuppressive therapy